Drug Target Review

APRIL 5, 2024

Together, these attributes provide a strong foundation for protein expression with enough adaptability to produce much of the commercial and therapeutic protein market. They’re prepared for complexity Successful expression of the gene of interest is not sufficient on its own for large-scale production.

Protein Production 96

Protein Production Protein Expression Bioinformatics Production 96

Drug Discovery World

NOVEMBER 8, 2023

The luncheon presentations include: Nikki Machalek, Scientist II, KBI Biopharma, on: ‘Comprehensive size distribution analysis of adeno-associated virus fill-states’. Peter Herr Neubauer, PhD, Lab Head, Bioprocess Engineering, TU Berlin, on: “Automated model based optimisation of difficult-to-express protein processes in a robotic facility”.

Engineering 162

Engineering Protein Expression Therapies Science 162

Drug Discovery World

APRIL 30, 2024

This is essential to its use as a therapeutic agent and gives the technology a vast versatility making it suitable to treating a wide range of diseases – especially those that have high protein expression. mRNA-based approaches can produce proteins / peptides by using protein synthesis which is processed in a transfected cell 1.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Drug Discovery World

NOVEMBER 9, 2023

Thereafter, there will be the following presentations: Georgios Skretas, PhD, Director, Institute for Bio-innovation, Biomedical Sciences Research Center “Alexander Fleming;” Founder & CEO, ResQ Biotech, on: ‘Development of specialised bacterial strains for high-level production of recombinant membrane proteins’.

Engineering 130

Engineering Therapies Protein Production Science 130

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52